11 March 2019

USD 100 million debt financing by Hercules Capital to Urovant Sciences

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to USD 100 million. Urovant plans to use the proceeds to fund ongoing development of its lead compound vibegron, for business development opportunities, and for general corporate purposes.

VISCHER advised Urovant Sciences as Swiss counsel. The VISCHER Team included Dr. Adrian Dörig (Partner, Banking & Finance), Ruben Masar (Senior Associate, Corporate), Julian Merz (Associate, Banking & Finance) and Christoph Niederer (Partner, Tax).

Share article on:

Service(s) included:

Get in touch with our authors and benefit from their expertise:

partner-Ruben-0

Ruben Masar

ruben.masar@vischer.com

+41 58 211 33 38

partner-Adrian-1

Adrian Dörig

adrian.doerig@vischer.com

+41 58 211 34 89

partner-Christoph-2

Christoph Niederer

christoph.niederer@vischer.com

+41 58 211 34 37

Our
newsletter

USD 100 million debt financing by Hercules Capital to Urovant Sciences